drugset / Trial / NCT06101316
A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China
NaSingle-groupOpen-labelTreatment
Summary
CB06-036 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Chronic Hepatitis B.
Timeline
- Start
- 2023-09-19
- Primary completion
- 2023-10-30
- Completion
- 2023-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB06-036 | Unknown | 1.5 mg | Oral |
Indications
No indication recorded.